© 2020 Chelation Partners

All Rights Reserved.

Scientific Advisors and Collaborators 

The extensive and positive preclinical results that have been obtained to date, many of which are now published in premier per-reviewed scientific journals,  have been the products of several years of effort by the Company’s researchers as well as by a number of collaborating research teams at Dalhousie University, McMaster University, the National Research Council of Canada (NRC) labs, teaching hospitals in Halifax, Nova Scotia and CROs -- Jubilant Life Sciences, Syngene/Biocon, Biovectra and Foresight Regulatory Strategies.
Principal Advisors and Collaborators involved with core development of anti-infective DIBI:
Craig Woods

DVM

Midwest U USA

(CPI board of directors)

 

Veterinary infection expert

Paul Fidel

Ph.D.

Louisiana State U USA

Antibiotic resistant fungal vaginal infection expert

Ross Davidson

Ph.D.

Director bacteriology QEII Hospital Halifax

Clinical microbiology expert 

Howard Xu

Ph.D.

Cal State U

Bacterial pneumonia expert

Matthias Bierenstiel

Ph.D.

Chair organic chemistry Cape Breton U Canada

Metal chemistry expert

Wangxue Chen

Ph.D.

HHTP National. Res. Council Canada

Bacterial pathogenesis expert

Lori Burrows

Ph.D.

DeGroote Infectious Dis. Res Inst Canada

Bacterial antibiotic resistance expert

Kendra Rumbaugh

Ph.D.

Texas Tech U USA

Pseudomonas burn/wound infection expert

Trialstat/ Jubilant Life Sciences Canada

CRO for DIBI toxicity studies

Other collaborator-led complementary platform aspects:
Christian Lehmann

MD

Dalhousie U

Inflammatory disease and bacterial sepsis expert

David Hoskin

Ph.D.

Dalhousie U

Breast cancer research chair, chemo resistant cancer expert